1.15
Schlusskurs vom Vortag:
$1.22
Offen:
$1.18
24-Stunden-Volumen:
758.96K
Relative Volume:
1.14
Marktkapitalisierung:
$72.55M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-0.7278
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
-22.30%
1M Leistung:
-49.56%
6M Leistung:
-67.61%
1J Leistung:
-91.59%
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Vergleichen Sie MGNX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MGNX
Macrogenics Inc
|
1.15 | 72.55M | 139.77M | -97.62M | -61.71M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2024-05-10 | Herabstufung | Stifel | Buy → Hold |
2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
2024-03-04 | Bestätigt | BTIG Research | Buy |
2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
2021-11-17 | Fortgesetzt | Guggenheim | Buy |
2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-10-15 | Fortgesetzt | BTIG Research | Buy |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
2020-03-04 | Eingeleitet | Barclays | Underweight |
2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
2019-04-12 | Eingeleitet | Guggenheim | Neutral |
2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
2018-09-10 | Fortgesetzt | BTIG Research | Buy |
2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
HC Wainwright Increases Earnings Estimates for MacroGenics - Defense World
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC Wainwright - Defense World
MGNX stock touches 52-week low at $1.88 amid market challenges - Investing.com Australia
MGNX stock touches 52-week low at $1.88 amid market challenges By Investing.com - Investing.com South Africa
MacroGenics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Canada
Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical - openPR.com
Macrogenics Inc (NASDAQ: MGNX) Analysts Prediction On How Much It Could Rise - Stocks Register
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Consensus Price Target from Analysts - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript - Insider Monkey
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook - Investing.com Canada
StockNews.com Downgrades MacroGenics (NASDAQ:MGNX) to Hold - Defense World
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook By Investing.com - Investing.com South Africa
MacroGenics Inc’s 2024 Earnings Call Highlights - TipRanks
MacroGenics axes ADC drug following Phase II failure in prostate cancer - Yahoo
Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahea - GuruFocus.com
Stifel maintains Hold on MacroGenics stock, price target at $6 By Investing.com - Investing.com Canada
Citizens JMP maintains MacroGenics stock with Market Outperform By Investing.com - Investing.com South Africa
Citizens JMP maintains MacroGenics stock with Market Outperform - Investing.com India
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates - MSN
MacroGenics Reports 2024 Financial Results and Progress - TipRanks
Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses - Yahoo Finance
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript - Yahoo
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
MACROGENICS Earnings Results: $MGNX Reports Quarterly Earnings - Nasdaq
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations - Investing.com India
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations By Investing.com - Investing.com UK
MacroGenics Inc. (MGNX) reports earnings - Quartz
MacroGenics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MacroGenics Inc Provides Update On Corporate Progress And 2024 Financial Results - Marketscreener.com
Macrogenics Inc (MGNX) Reports Q4 Revenue of $150 Million, Surpa - GuruFocus
MACROGENICS INC SEC 10-K Report - TradingView
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - GlobeNewswire
MacroGenics Triples Revenue to $150M as Cancer Drug Pipeline Advances - StockTitan
MGNX stock touches 52-week low at $2.15 amid sharp annual decline - Investing.com Australia
Macrogenics Stock Drops 77% After Study Deaths - The Wall Street Journal
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships By Investing.com - Investing.com South Africa
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com
MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com
MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):